KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema

• Published in: American journal of ophthalmology Vol. 260; pp. 70 - 83
• Main Authors: Wykoff, Charles C., Garweg, Justus G., Regillo, Carl, Souied, Eric, Wolf, Sebastian, Dhoot, Dilsher S., Agostini, Hansjuergen T., Chang, Andrew, Laude, Augustinus, Wachtlin, Joachim, Kovacic, Lidija, Wang, Lixin, Wang, Ying, Bouillaud, Emmanuel, Brown, David M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2024
• Subjects: Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized; Diabetes Mellitus; Diabetic Retinopathy - complications; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Humans; Intravitreal Injections; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - etiology; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Recombinant Fusion Proteins - therapeutic use; Treatment Outcome; Visual Acuity

To report the 100-week outcomes from the KESTREL and KITE trials. Two phase 3, double-masked, active-controlled, randomized trials. Patients with diabetic macular edema (DME) were randomized 1:1:1 to brolucizumab 3 mg/6 mg (BRO3/BRO6) or aflibercept 2 mg (AFL) in KESTREL (N = 566) or 1:1 to BRO6 or...